Hearing loss and cognitive decline often travel together. A major randomized trial tested whether treating one could change the other—and found an answer more complicated than either “yes” or “no.”
A conversation in a crowded restaurant becomes harder to follow. The television volume creeps upward. Words need repeating. What seems like a problem with the ears gradually makes ordinary communication require more effort.
But researchers have noticed something more surprising: older adults with hearing loss are also more likely to experience cognitive decline and dementia.
A 2024 systematic review combining 50 cohort studies and more than 1.5 million people found that adult-onset hearing loss was associated with a 35% higher rate of developing dementia. Greater hearing loss was associated with greater risk.
That is an important finding—and an easy one to misread.
An association does not tell us that hearing loss causes dementia. People with hearing loss may differ in age, cardiovascular health, education, social engagement, healthcare access, and other factors that also matter for cognitive aging. Hearing and cognitive decline could also share some underlying causes.
So the more important question is not whether hearing loss and dementia are connected.
It is this:
If you actually treat hearing loss, can you slow cognitive decline?
For years, there was surprisingly little strong evidence to answer that question.
Then researchers ran a large randomized trial designed to find out.
Hearing Loss Is a Risk Marker—but Is It a Modifiable One?
The connection between hearing and cognition has appeared repeatedly in observational research.
Across large populations, people with hearing loss tend to experience higher subsequent rates of cognitive impairment and dementia. In the 2024 meta-analysis, each additional 10-decibel worsening in hearing was associated with a 16% higher rate of dementia.
That consistency makes the relationship difficult to dismiss.
But it still cannot tell us what would happen if hearing improved.
This is the difference between identifying a risk marker and identifying a modifiable cause.
Imagine that people who obtain hearing aids also tend to have better access to healthcare, more resources, or healthier lifestyles. If they later experience less cognitive decline, hearing treatment might deserve some of the credit—but perhaps not all of it.
Or hearing loss and cognitive decline might partly reflect other processes associated with aging. Treating the hearing loss would then improve hearing without necessarily changing what is happening in the brain.
There are also plausible reasons to think treatment could matter.
When hearing becomes difficult, following a conversation can require more concentration. Instead of simply understanding speech, you may need to reconstruct missing words and continually check whether you heard correctly. Hearing problems may also make social situations less rewarding or more exhausting, potentially reducing participation in activities that provide cognitive and social stimulation.
Those ideas help explain why scientists suspected a connection.
They do not prove that hearing aids protect cognition.
For that, researchers needed an experiment.
The ACHIEVE Trial Put the Idea to a Much Harder Test
The Aging and Cognitive Health Evaluation in Elders trial—ACHIEVE—was the first large randomized trial specifically designed to test whether treating hearing loss could slow cognitive decline over several years.
The US study enrolled 977 adults ages 70 to 84 with untreated hearing loss who did not have substantial cognitive impairment.
Half received a comprehensive hearing intervention that included hearing aids and audiological counseling. The other half participated in a health-education program covering chronic-disease prevention. Researchers followed both groups for three years and repeatedly measured cognitive performance.
If you have heard that this trial proved hearing aids protect the aging brain, its primary result may be surprising.
Across all 977 participants, they did not significantly slow cognitive decline.
Global cognition changed at essentially the same rate in the hearing-intervention and health-education groups.
That is the trial’s primary result, and it matters.
But it was not the whole result.
The participants had come from two quite different populations.
Most—739 people—were relatively healthy volunteers recruited from the community. Another 238 were participants in the long-running Atherosclerosis Risk in Communities, or ARIC, study. The ARIC participants were older on average, had more risk factors for cognitive decline, and started with lower cognitive scores.
During the trial, those higher-risk participants also declined much faster.
Among people assigned to the control group, cognitive decline in the ARIC participants was roughly 2.7 times faster than in the healthier volunteers.
And when researchers examined the two populations separately in a prespecified analysis, something striking appeared.
In the higher-risk ARIC group, the hearing intervention was associated with a 48% slower rate of global cognitive decline over three years.
Among the healthier community volunteers, there was no significant cognitive benefit.
So the same intervention appeared to have very different effects depending on who received it.
The People at Greater Risk May Have Had More to Gain
Why would hearing treatment appear to help one group but not the other?
One possible explanation is straightforward: there was much more cognitive decline available to slow in the higher-risk participants.
The healthier volunteers declined relatively little during the three-year study. Detecting whether an intervention can slow an already slow change is difficult.
The ARIC participants were declining faster.
A later secondary analysis of ACHIEVE examined this idea more directly. Researchers estimated participants’ baseline risk of cognitive decline using information collected before treatment.
The pattern strengthened as risk increased.
Among participants in the highest quarter of predicted cognitive risk, the hearing intervention was associated with a 62% slower rate of cognitive decline over three years.
That does not mean clinicians can now calculate someone’s cognitive risk and determine whether hearing aids will protect their brain. The risk analysis was secondary, not a separate randomized trial designed to validate a treatment threshold.
But it helps explain an otherwise puzzling result.
The hearing intervention may not produce the same measurable cognitive effect in everyone. Its impact may be easier to detect—and potentially more important—among people already at greater risk of decline.
This is why two statements about ACHIEVE can both be true:
The trial found no significant cognitive benefit overall.
It also found a substantial benefit in its higher-risk study population.
Neither statement means hearing aids have been shown to prevent dementia.
Slowing Cognitive Decline Is Not the Same as Preventing Dementia
The distinction is crucial.
The often-cited 48% figure refers to the rate of change on cognitive tests over three years in one subgroup of ACHIEVE.
It does not mean hearing treatment reduced someone’s chance of developing dementia by 48%.
ACHIEVE was not evidence of a 48% reduction in Alzheimer’s disease or dementia diagnoses.
Before the trial, observational research had made the case for cognitive protection look promising. A 2023 systematic review and meta-analysis involving more than 137,000 people with hearing loss found that use of hearing-restoration devices was associated with a 19% lower hazard of long-term cognitive decline, including incident dementia.
But most of the studies contributing to that long-term result were observational.
That matters because people who use hearing aids may differ from people who do not in ways that statistical adjustment cannot completely remove. Random assignment is valuable precisely because it helps separate the effect of treatment from those differences.
ACHIEVE therefore deserves particular weight.
And its randomized answer is deliberately uncomfortable for anyone looking for a simple headline: no significant slowing of cognitive decline across the entire trial, but a meaningful signal of benefit among participants at greater cognitive risk.
There is another limitation: time.
Three years is substantial for a randomized hearing trial but short compared with the long process through which dementia develops. Showing slower change on cognitive tests over three years is not equivalent to demonstrating fewer dementia diagnoses years later.
But the reverse conclusion would also be unjustified.
“Not proven to prevent dementia” does not mean “proven not to help.”
The stronger claim simply remains unanswered.
Hearing Loss Is Still Worth Treating Without a Dementia Promise
It is easy for the dementia question to overshadow something more immediate.
Hearing treatment does not need to prevent cognitive decline to be worthwhile.
In ACHIEVE, the intervention clearly improved the problem it was designed to treat. People receiving hearing care reported substantially less difficulty communicating, and that advantage persisted throughout the three-year study.
That benefit matters on its own.
Being able to follow conversations more easily and communicate with less difficulty improves something people experience in everyday life—not a hypothetical future outcome.
Possible cognitive protection is better viewed as an encouraging additional possibility, particularly for older adults already at elevated risk of cognitive decline, rather than as a promise attached to hearing aids.
The research cannot yet tell an individual, “Treating your hearing loss will preserve your cognition.” It certainly cannot promise that hearing aids will prevent dementia.
What it can tell us is more interesting than it could a few years ago.
The association between hearing loss and cognitive decline is not merely an observational curiosity anymore. Researchers have now tested whether intervening on hearing can change cognitive trajectories—and among some higher-risk older adults, it appeared to do exactly that.
The next question is whether that benefit holds up over longer follow-up and ultimately translates into outcomes that matter even more, including the development of cognitive impairment or dementia.
For now, the distinction is clear:
Treating hearing loss helps people hear and communicate better. We do not yet know that it prevents dementia. But randomized evidence now suggests that, for some older adults at greater risk of cognitive decline, better hearing may also help the aging brain decline more slowly.
